<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29439646</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2018</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>6</Issue><PubDate><Year>2018</Year><Month>May</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>The influence of functional polymorphic positions of HLA-DR&#x3b2;1 molecules on risk for South Indian systemic lupus erythematosus patients.</ArticleTitle><Pagination><StartPage>991</StartPage><EndPage>1000</EndPage><MedlinePgn>991-1000</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0961203318759200</ELocationID><Abstract><AbstractText>The aim of this case-control study was to investigate the association of human leukocyte antigen (HLA) Class II alleles with the susceptibility and phenotypic heterogeneity in systemic lupus erythematosus (SLE) in South Indian patients. A total of 439 individuals (212 SLE cases and 227 age- and ethnicity-matched controls) were included in the study. The genotyping of HLA-DR&#x3b2;1 and - DQ&#x3b2;1 was conducted by the PCR-SSP method. HLA-DR&#x3b2;1*07 was significantly associated with SLE (OR: 2.02; 95% CI: 1.34-3.04, p&#x2009;=&#x2009;1.50&#x2009;&#xd7;&#x2009;10<sup>-4</sup>, p<sub>c</sub>&#x2009;=&#x2009;1.95&#x2009;&#xd7;&#x2009;10<sup>-3</sup>), whereas the DR&#x3b2;1*14 allele was negatively associated with SLE (OR: 0.49; 95% CI: 0.31-0.76, p&#x2009;=&#x2009;1.70&#x2009;&#xd7;&#x2009;10<sup>-2</sup>, p<sub>c</sub>&#x2009;=&#x2009;0.221). In addition, the HLA-DR&#x3b2;1*07/15 genotype tended to be positively associated with SLE (OR: 3.23, 95% CI: 1.57-6.63, p&#x2009;=&#x2009;0.0009). Amino acid residues residing in the peptide-binding pocket of HLA-DR&#x3b2;1 play a significant role in peptide recruitment and antigen presentation. Our results demonstrated that amino acid glycine 11 (OR: 2.11, 95% CI: 1.42-3.12, p<sub>c</sub>&#x2009;=&#x2009;0.00093), tyrosine 13 (OR: 2.11, 95% CI: 1.42-3.12, p<sub>c</sub>&#x2009;=&#x2009;0.00062) and glutamine 74 (OR: 2.11, 95% CI: 1.42-3.12, p<sub>c</sub>&#x2009;=&#x2009;0.00077) showed a significant positive association with SLE. Certain haplotype combinations, DRB1*07-DQ&#x3b2;1*03 (OR: 2.21; 95% CI:1.29-3.79, p<sub>c</sub>&#x2009;=&#x2009;0.06, p&#x2009;=&#x2009; 0.00036) and DR&#x3b2;1*07-DQ&#x3b2;1*05 (OR: 2.51, 95% CI: 1.34-4.71, p<sub>c</sub>&#x2009;=&#x2009;0.07, p&#x2009;=&#x2009;0.00039), had positive associations whereas DR&#x3b2;1*14-DQ&#x3b2;1*03 (OR: 0.14, 95% CI: 0.061-0.36, p<sub>c</sub>&#x2009;=&#x2009;2.34&#x2009;&#xd7;&#x2009;10<sup>-5</sup>, p&#x2009;=&#x2009;1.30&#x2009;&#xd7;&#x2009;10<sup>-6</sup>) were found to have a significant negative association with SLE. So far, the present study is the first attempt to investigate the association of HLA-DR&#x3b2;1 and - DQ&#x3b2;1 allele, genotype and haplotype combinations with the risk of SLE in South Indian patients. In conclusion, the HLA-DR&#x3b2;1*07 allele is associated with risk of SLE whereas a protective association of HLA-DR&#x3b2;1*14 alleles with SLE was observed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Katkam</LastName><ForeName>S K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>1 Department of Clinical Pharmacology and Therapeutics, 28605 Nizam's Institute of Medical Sciences (NIMS) , Telangana, Hyderabad, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajasekhar</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>2 Department of Clinical Immunology and Rheumatology, 28605 Nizam's Institute of Medical Sciences (NIMS) , Telangana, Hyderabad, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kutala</LastName><ForeName>V K</ForeName><Initials>VK</Initials><AffiliationInfo><Affiliation>1 Department of Clinical Pharmacology and Therapeutics, 28605 Nizam's Institute of Medical Sciences (NIMS) , Telangana, Hyderabad, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>02</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059866">HLA-DQ beta-Chains</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C069051">HLA-DQB1 antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059811">HLA-DRB1 Chains</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C456920">HLA-DRB1*07 antigen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059866" MajorTopicYN="N">HLA-DQ beta-Chains</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059811" MajorTopicYN="N">HLA-DRB1 Chains</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N">India</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065840" MajorTopicYN="N">Protective Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">autoantibody</Keyword><Keyword MajorTopicYN="N">autoimmune disease</Keyword><Keyword MajorTopicYN="N">human leukocyte antigen</Keyword><Keyword MajorTopicYN="N">major histocompatibility complex</Keyword><Keyword MajorTopicYN="N">polymorphism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29439646</ArticleId><ArticleId IdType="doi">10.1177/0961203318759200</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>